Unlabelled: Identification of early-stage Alzheimer's disease (AD) remains a challenge due to limited specialist availability, diagnostic access, disease awareness, and cultural factors. Blood-based biomarkers (BBBM) could play a critical role in the identification and referral of patients suspected of AD to specialty care. A multidisciplinary AD Biomarker Task Force was convened to evaluate current biomarker use cases, define an optimal biomarker-enabled AD diagnostic care pathway, and understand factors impacting adoption. The Task Force identified opportunities to support biomarker-enabled AD diagnostic care pathway adoption, including streamlining risk assessment and screening by leveraging digital tools, activating primary care providers through education, generating data to expand applicability to diverse populations, and advocating for aligned policies and quality measures. Adoption of BBBMs in the primary care setting will be critical to improve early AD detection. However, challenges to pathway adoption persist and will require action from clinicians, payers, policy makers, and patients to address.
Highlights: Blood-based biomarkers can streamline the identification of AD in primary care.Future biomarker-enabled diagnostic care pathways will leverage digital assessments.Education, data generation, and policy advocacy are vital to encourage BBBM use.Implementation of AD care pathways requires the activation of diverse stakeholders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895972 | PMC |
| http://dx.doi.org/10.1002/dad2.70095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting hepatocellular carcinoma metastasis.
Hepatology
March 2025
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.
Background And Aims: Portal vein tumor thrombosis (PVTT), an indicator of clinical metastasis, significantly shortens hepatocellular carcinoma (HCC) patients' lifespan, and no effective treatment has been established. We aimed to illustrate mechanisms underlying PVTT formation and tumor metastasis, and identified potential targets for clinical intervention.
Approach And Results: Multi-omics data of 159 HCC patients (including 37 cases with PVTT) was analyzed to identify contributors to PVTT formation and tumor metastasis.
Postoperative adhesions are abrogated by a sustained-release anti-JUN therapeutic in preclinical models.
Sci Transl Med
March 2025
Hagey Laboratory for Pediatric Regenerative Medicine, Division of Plastic and Reconstructive Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Postoperative abdominal adhesions are the leading cause of bowel obstruction and a cause of chronic pain and infertility. Adhesion formation occurs after 50 to 90% of abdominal operations and has no proven preventative or treatment strategy. Abdominal adhesions derive primarily from the visceral peritoneum and are composed of polyclonally proliferating tissue-resident fibroblasts.
View Article and Find Full Text PDFEnhanced packaging of U6 small nuclear RNA and splicing-related proteins into extracellular vesicles during HIV infection.
Sci Adv
March 2025
Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
U6 small nuclear RNA (U6 snRNA), a critical spliceosome component primarily found in the nucleus, plays a vital role in RNA splicing. Our previous study, using the simian immunodeficiency virus (SIV) macaque model, revealed an increase of U6 snRNA in plasma extracellular vesicles (EVs) in acute retroviral infection. Given the limited understanding of U6 snRNA dynamics across cells and EVs, particularly in SIV infection, this research explores U6 snRNA trafficking and its association with splicing proteins in the nucleus, cytoplasm, and EVs.
View Article and Find Full Text PDFDirect Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization.
ACS Nano
March 2025
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Shanghai 200080, China.
Small interfering RNA (siRNA) has garnered tremendous interest as a potential therapeutic tool because of its intriguing gene-silencing ability. Toward the success in the manufacture of siRNA therapeutics for the potential treatment of choroidal neovascularization (CNV), siRNA conjugated with dual functional units of membrane-penetrating heptafluoropropyl and age-related macular degeneration-targeting cyclic Arg-Gly-Asp (RGD) peptide was attempted for transcellular transportation into the cell interiors. Of note, cyclic RGD allowed selective affinities toward the angiogenic endothelial cells in the pathological CNV.
View Article and Find Full Text PDFIndividualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.
J Infus Nurs
March 2025
Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!